Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127171131 | 12717113 | 1 | I | 20160708 | 20160903 | 20160906 | 20160906 | EXP | PHHY2016BR122323 | NOVARTIS | 92.45 | YR | F | Y | 74.00000 | KG | 20160906 | MD | BR | BR |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127171131 | 12717113 | 1 | PS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 4.6 MG QHS, PATCH 5 (CM2) | 22083 | 4.6 | MG | TRANS-THERAPEUTIC-SYSTEM | |||||||
127171131 | 12717113 | 2 | SS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | UNK UNK, QD | 22083 | TRANS-THERAPEUTIC-SYSTEM | QD | ||||||||
127171131 | 12717113 | 3 | SS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 13.3 MG QD, PATCH 15 (CM2) | 22083 | 13.3 | MG | TRANS-THERAPEUTIC-SYSTEM | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127171131 | 12717113 | 1 | Parkinson's disease |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
127171131 | 12717113 | DE |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127171131 | 12717113 | Cerebral thrombosis | |
127171131 | 12717113 | Cerebrovascular accident | |
127171131 | 12717113 | Product use issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |